Core Viewpoint - GE HealthCare Technologies (GEHC) has launched CareIntellect for Oncology, a cloud-first application that integrates multi-modal patient data using generative AI to enhance clinical decision-making and patient care. Group 1: Product Launch and Features - CareIntellect for Oncology will initially focus on breast and prostate cancer, providing a comprehensive view of patient data to streamline treatment assessments and clinical trial eligibility [1][4] - The application organizes both structured and unstructured data, reducing the time clinicians spend on gathering patient histories from multiple systems [2][3] - It will be available to U.S. consumers in 2025, with plans for expansion to Canada, the UK, and Ireland [4] Group 2: Market Performance and Financials - Following the announcement, GEHC shares fell by 1.7% to $89.80, but have increased by 16.2% year-to-date, outperforming the industry which declined by 9.6% [2] - GEHC has a market capitalization of $41.01 billion and an earnings yield of 4.74%, significantly higher than the industry's negative yield of 8.78% [2] Group 3: Industry Trends and Opportunities - The global generative AI in healthcare market is projected to grow from $1.6 billion in 2022 to over $30.4 billion by 2032, with a CAGR of 34.9% [5] - The increasing volume of healthcare data and the shortage of healthcare workers are driving the adoption of AI solutions in clinical settings [5] Group 4: Recent Developments in AI - GEHC has launched Versana Premier, an AI-enabled ultrasound system, and acquired Intelligent Ultrasound Group PLC's clinical AI software business to enhance its ultrasound portfolio [6] - The company also introduced Venue Sprint, a portable ultrasound system designed for point-of-care use, equipped with advanced AI tools [6][7]

GE Healthcare booth is seen ahead of the 2022 China International Fair for Trade in Services (CIFTIS) at China National Convention Center on August 28, 2022 in Beijing, China."For cancer patients, the treatment journey can last years and involve numerous doctor visits," he said.CareIntellect for Oncology will be able to summarize clinical reports and identify when patients are deviating from their treatment plans, Kass-Hout said. The system can flag when a patient misses a lab test, for instance, so that th ...

GE HealthCare (GEHC) completed the acquisition of Intelligent Ultrasound Group PLC's clinical artificial intelligence (AI) software business, a move aimed at reshaping its ultrasound portfolio. The deal, signed in July 2024, is valued at $51 million and aligns with GE HealthCare's broader strategy of integrating AI to enhance patient outcomes, improve clinical workflows and advance medical imaging. This acquisition, along with the earlier deals, is set to strengthen GE HealthCare's capabilities in the compe ...

GE Healthcare's (GEHC) MIM Software recently announced the receipt of FDA clearance for its Monte Carlo Dosimetry, marking a significant advancement in theranostics. This innovative solution is designed to improve the precision of radiation dose calculations for personalized treatment plans in nuclear medicine, particularly for patients receiving radiopharmaceutical therapies. The technology is pivotal in tailoring treatments specifically to the individual needs of patients, thereby maximizing therapeutic b ...

GE HealthCare Technologies, Inc. (GEHC) is well-poised for growth in the coming quarters, courtesy of its continued focus on innovations. The optimism, led by strong second-quarter fiscal 2024 performance and acquisitions, is expected to contribute further. However, geopolitical tensions and stiff competition are concerning. This Zacks Rank #3 (Hold) company's shares have gained17.8% in the year-to-date period against 8.8% decline of the industry. The S&P 500 Composite has risen 20% during the said time fra ...

Shares of GE HealthCare Technologies Inc (NASDAQ:GEHC), a spinoff of General Electric (GE), are down 1.9% before the opening bell after a bear note from UBS. The analyst downgraded GEHC to "sell" from "neutral," citing worries over near- to mid-term growth potential and vulnerability to competition in the Chinese Medtech market. Of the 18 brokerages covering GE HealthCare stock, 11 carried a "strong buy" recommendation coming into today, while the remaining seven rated it a lukewarm "hold." This leaves plen ...

GE HealthCare Technologies, Inc (GEHC) has introduced Venue Sprint, a new portable ultrasound system designed to meet the growing demand for point-of-care ultrasound across various healthcare settings. Equipped with powerful Venue software, AI-enabled tools and wireless Vscan Air dual-probes, the Venue Sprint delivers high-quality imaging and real-time insights in critical care, emergency medicine and medical transport environments. The device enhances workflow efficiency by simplifying learning, offering e ...

By most accounts, things have been going quite well for shareholders of GE HealthCare Technologies (NASDAQ: GEHC ). I have followed the company for a long time. I even analyzed it when it was part of the former conglomerate Crude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential. Subscribers get to use a 50+ stock model account, in-depth cash flow ana ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Considering buying GEHC stock? Here's what analysts think: GE HealthCare Technologies Inc has a consensus price target of $94.81 based on the ratings of 18 analysts. The high is $110 issued by Argus Research on April 1, 2024. The low is $80 issued by Jefferies on November 30, 2023. The 3 most-recent analyst ratings were ...

GE Healthcare Technologies Inc. (GEHC) has announced the receipt of the CE mark for its Vscan Air SL wireless handheld ultrasound system with Caption AI. The company also received the CE mark for the use of ECG-less cardiac computed tomography (CT) scanning on its Revolution Apex platform. The Vscan Air SL with Caption AI facilitates rapid cardiac assessments at the point of care, enabling even nonexperts to capture high-quality cardiac images. It provides real-time visual guidance and automated calculation ...